Spigset O. Gentesting før behandling med warfarin? Tidsskr Nor Legeforen 2009; 129: 843.
Link
Spigset O. Farmakogenetikk i praksis. Tidsskr Nor Lægeforen; 2008; 128: 1679.
Link
Güzey C, Scordo MG, Spina E, Landsem VM, Spigset O. Antipsychotic-induced extrapyramidal symptoms in patients with schizophrenia: associations with dopamine and serotonin receptor and transporter polymorphisms. Eur J Clin Pharmacol 2007; 63: 233-41.
Link
Spigset O. Skreddersydd legemiddelbehandling – hvor nær målet er vi? Tidsskr Nor Lægeforen 2006, 126: 2390-6.
Link
Hedenmalm K, Güzey C, Dahl M-L, Yue Q-Y, Spigset O. Risk factors for extrapyramidal symptoms during treatment with selective serotonin reuptake inhibitors, including cytochrome P-450 enzyme and serotonin and dopamine transporter and receptor polymorphisms. J Clin Psychopharmacology 2006; 26: 192-7.
Link
Güzey C, Spigset O. Low serum concentrations of paroxetine in two CYP2D6 ultrarapid metabolizers. J Clin Psychopharmacology 2006; 26: 211-2.
Link